Morgan Stanley's weekly tracker shows total US prescription growth decelerated to 1.5% YoY for the week ended July 31. Among individual drugs, GILD's Yeztugo stood out: Morgan Stanley sees $1.049B in US sales vs $988M consensus, citing strong persistence and payer coverage. Script counts for BMY, VRTX, and JNJ drugs were stable to slightly higher.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
